Central nervous system disease

AVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on:

Thursday, April 4, 2024

Central nervous system, Patient, CNS, Research, Neurodevelopmental disorder, News, Avatar, Rett syndrome, Complaint, Fraud, Excellence, FDA, Central nervous system disease, Court, Person, Pharmaceutical industry

Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.

Key Points:

Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.
or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
If you suffered a loss in Anavex you have until May 13, 2024, to request that the Court appoint you as lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

ANAVEX LIFE SCIENCES CORPORATION (NASDAQ: AVXL) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Anavex Life Sciences Corporation

Retrieved on:

Monday, April 1, 2024

Central nervous system, District court, Patient, CNS, Research, Neurodevelopmental disorder, News, Avatar, Rett syndrome, Complaint, Action Replay, Excellence, FDA, Central nervous system disease, Court, Advertising

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Key Points:

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
Do you, or did you, own shares of Anavex Life Sciences Corporation (NASDAQ: AVXL)?
If you wish to serve as lead plaintiff, you must move the Court no later than May 13, 2024.
A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

AVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on:

Thursday, March 28, 2024

Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.

Key Points:

Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.
or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
If you suffered a loss in Anavex you have until May 13, 2024, to request that the Court appoint you as lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

ANAVEX LIFE SCIENCES CORPORATION (NASDAQ: AVXL) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Anavex Life Sciences Corporation

Retrieved on:

Monday, March 25, 2024

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Key Points:

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
Do you, or did you, own shares of Anavex Life Sciences Corporation (NASDAQ: AVXL)?
If you wish to serve as lead plaintiff, you must move the Court no later than May 13, 2024.
A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

AVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on:

Thursday, March 21, 2024

Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.

Key Points:

Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.
or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
If you suffered a loss in Anavex you have until May 13, 2024, to request that the Court appoint you as lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

ANAVEX LIFE SCIENCES CORPORATION (NASDAQ: AVXL) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Anavex Life Sciences Corporation

Retrieved on:

Monday, March 18, 2024

NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Key Points:

NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
Do you, or did you, own shares of Anavex Life Sciences Corporation (NASDAQ: AVXL)?
If you wish to serve as lead plaintiff, you must move the Court no later than May 13, 2024.
A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

AVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on:

Thursday, March 14, 2024

Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.

Key Points:

Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.
or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
If you suffered a loss in Anavex you have until May 13, 2024, to request that the Court appoint you as lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

ANAVEX LIFE SCIENCES CORPORATION SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Anavex Life Sciences Corporation (NASDAQ: AVXL)

Retrieved on:

Thursday, March 14, 2024

NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Key Points:

NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
Do you, or did you, own shares of Anavex Life Sciences Corporation (NASDAQ: AVXL)?
Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the stock of Anavex Life Sciences Corporation (“Anavex” or the “Company”) (NASDAQ: AVXL) between February 1, 2022 and January 1, 2024, inclusive (the “Class Period”).
If you purchased or acquired Anavex stock, and/or would like to discuss your legal rights and options please visit Anavex Life Sciences Corporation Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .
The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

AVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on:

Thursday, March 21, 2024

Class Action Lawsuit, Professional Services, Legal, Central nervous system, Patient, CNS, Research, Neurodevelopmental disorder, News, Avatar, Rett syndrome, Complaint, Fraud, Excellence, FDA, Central nervous system disease, Court, Person, Pharmaceutical industry

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Anavex Life Sciences Corp. (“Anavex” or “the Company”) (NASDAQ: AVXL) and certain of its officers.

Key Points:

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Anavex Life Sciences Corp. (“Anavex” or “the Company”) (NASDAQ: AVXL) and certain of its officers.
Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.
or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on:

Thursday, March 21, 2024

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.

Key Points:

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.
In January 2023, Alto reported positive results from a Phase 2a study in which patients with MDD and a cognitive biomarker signature were identified as more responsive to ALTO-100.
Alto is currently evaluating ALTO-100 in a 266-patient Phase 2b study in MDD patients characterized by the cognitive biomarker.
The increase was primarily attributable to costs associated with the Phase 2a clinical studies for ALTO-100 and ALTO-300, which were completed in 2023.